Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

When Will We Be Able to Invest in Impossible Foods Stock?

By Dana Blankenhorn, InvestorPlace Contributor

Jay-Z and Katy Perry can get rich from plant-based meat, but without an IPO, us little guys can't invest in Impossible Foods stock.

Is Skyworks Solutions Stock Still an Apple Proxy as Tim Cook Eyes Own Chips

By Dana Blankenhorn, InvestorPlace Contributor

Skyworks is up 26% this year and the SWKS stock dividend yield is no longer worth chasing, but that's less than one-third Apple's gain.

Advanced Micro Devices: Great Company, Overvalued Stock

By Dana Blankenhorn, InvestorPlace Contributor

Dr. Lisa Su has done an incredible job for AMD shareholders since becoming CEO in 2014, but you don't have a profit until you sell and have the cash in your pocket.

AAPL Stock Investors Showing Lots of Love as Apple Chip Design Takes Hold

By Dana Blankenhorn, InvestorPlace Contributor

Apple is now designing its own chips for fabrication by Taiwan Semiconductor. AAPL stock is poised to gain as performance improves, margins increase, and the tech maker guarantees its dominance through this decade.

Is CRISPR Therapeutics Worth It Without Drugs?

By Dana Blankenhorn, InvestorPlace Contributor

We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.

Load More